Wyniki wyszukiwania - BazTech

1

Development and validation of a rapid UHPLCMS/MS method for the determination of fenofibric acid in human plasma: application to a pharmacokinetic study of fenofibrate tablet in Chinese subjects

Wu Xiaorong, Wang Yankai, Liang Binbin, Wu Honghai, Wu Liying, Song Jing, Liu Jianfang

Acta Chromatographica

|

2021

|

Vol. 33, no. 4

309--314

EN

An ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC–MS/MS) method was developed to determine the fenofibric acid (FA) in human plasma and applied to a pharmacokinetic study of fenofibrate tablet (Lipanthyl® supra, 160 mg) on Chinese subjects which had not been reported. Bezafibrate was used as an internal standard (IS), and the plasma samples were precipitated by methanol. Multiple reaction monitoring (MRM) mode was used to quantitatively analyzed FA m/z 317.2→230.7 and the IS m/z 360.0→274.0 in the electrospray ionization (ESI) negative interface. The calibration curves were linear over the range of 50–30,000 ng/mL (r2 ≥ 0.996). The intra-day and interday precision (coefficient of variation, CV%) was less than 2.7 and 2.5%, respectively. The accuracy (relative error, RE%) ranged from 4.5 to 6.9%. The average recovery was higher than 86.2%, and the matrix effect was between 95.32 and 110.55%. The simple, rapid, and selectivity method was successfully applied to the pharmacokinetic study of fenofibrate tablets on Chinese subjects.

2

Determination of sarecycline by UPLC-MS/MS and its application to pharmacokinetic study in rats

Shen Yonghui, Meng Deru, Chen Feifei, Jiang Hui, Liming Hu, Zhou Yunfang, Zhang Miaomiao

Acta Chromatographica

|

2021

|

Vol. 33, no. 3

228--233

EN

Sarecycline is a narrow-spectrum antibiotic for the treatment of acne, which is a chronic inflammatory disease of the hair follicle sebaceous glands. In the study, UPLC-MS/MS was used to establish a rapid and accurate analytical method. The sarecycline was determined with poziotinib as internal standard (IS) in rat plasma. An ACQUITY UPLC HSS T3 column (2.1 × 100 mm, 1.8 μm) could performe chromatographic separation with the mobile phase (methanol: water of 0.1% formic acid) with gradient elution. The ions of target fragment were m/z 488.19→410.14 for sarecycline and m/z 492.06→354.55 for poziotinib, which could quantify the electrospray ionization of positive multiple reaction monitoring (MRM) mode. The linear calibration curve of the concentration range was 1–1,000 ng/mL for sarecycline with a lower limit of quantification (LLOQ) of 1 ng/mL. The mean recovery was between 82.46 and 95.85% for sarecycline and poziotinib in rat plasma. RSD for precision of inter-day and intra-day were between 3.24 and 13.36%, and the accuracy ranged from 105.26 to 109.75%. The developed and validated method was perfectly used in the pharmacokinetic study and bioavailability of sarecycline after intravenous and oral administration in rats.

3

Development and validation of a gradient elution high-performance liquid chromatographic method for determination of talinolol in rat plasma: Application to a preclinical food-drug interaction study

Mahgoub H, Hanafy A., Bamane F. H., Radwan A. E.

Acta Chromatographica

|

2015

|

Vol. 27, no. 1

67--79

EN

A sensitive and reproducible high-performance liquid chromatographic (HPLC) method for determination of talinolol (TAL) in rat plasma was developed and validated using pindolol (PIN) as an internal standard. Both TAL and PIN were separated on a Zorbax Eclipse XDB C18 column by gradient elution with 0.1% aqueous formic acid and acetonitrile as the mobile phase. Detection was performed using fluorescence measurement at λex 249 nm and λem 333 nm. The method was validated and found to be linear in the range of 10–2000 ng mL−1. The limit of quantification was 10 ng mL−1 based on 100 μL of plasma. The variations for intra- and inter-day precision were less than 10%, and the accuracy values were between 92% and 102.9%. The extraction recoveries were more than 82%. The assay was successfully applied to an in-vivo pharmacokinetic study of TAL in rats that were administered a single oral dose of 10 mg kg−1 TAL. The maximum concentration (Cmax) and the area under the plasma concentration-time curve (AUC0–12) were 0.369 ± 0.024 μg mL−1 and 1.429 ± 0.027 μg h mL−1, respectively. The modulatory effect of apricot juice on P-glycoprotein-related efflux carriers was also investigated. Co-administration of apricot juice resulted in a significant increase of the amount of TAL in plasma (Cmax and AUC0–12 were 0.679 ± 0.021 and 2.357 ± 0.079, respectively; p < 0.05).

4

Simultaneous quantification of salvianolic acid B and tanshinone IIA of salvia tropolone tablets by UPLC-MRM-MS/MS for pharmacokinetic studies

Li J. R., Li D. X., Li L., Deng W. L., Ding L. S., Xu H. X., Zhou Y.

Acta Chromatographica

|

2014

|

Vol. 26, no. 4

711--725

EN

A rapid and sensitive ultraperformance liquid chromatography-multiple reaction monitoring-multi-stage/mass spectrometry (UPLC-MRM-MS/MS) method has been developed for simultaneous quantification of salvianolic acid B and tanshinone IIA of salvia tropolone tablets in dog plasma. This was achieved by performing quantification using the MRM acquisition with two channels of MRM-MS/MS and MS full scan for more accuracy qualitative results, and the fragmentation transitions of m/z 295→249, 191 for tanshinone IIA and m/z 297→279, 251 for IS in positive mode, m/z 717→519, 321 for salvianolic acid B and m/z 295→267, 239 for IS in negative mode were selected. The UPLC separation was achieved within 3 min in a single UPLC run. Linear calibration curves were obtained over the concentration range of 10 pg/mL-1 ng/mL for tanshinone IIA and 100 pg/mL-1 for salvianolic acid B. Lower limit of quantitation (LLOQ) was 10 pg/mL and 100 pg/mL for tanshinone IIA and salvianolic acid B, respectively. The inter-day and intra-day precision (relative standard deviation, RSD) in all samples were less than 8.21%, and the recoveries were over 85.9% for both tanshinone IIA and salvianolic acid B. The two channels of MRM with MS full scan approach could provide both qualitative and quantitative results without the need for repetitive analyses and resulted in the reduction of further confirmation experiments and analytical time. The pharmacokinetic study of the two active components of salvia tropolone tablets following oral gavage administration of dogs was thus explored with this method.

5

A simple HPLC method for determining 2-(3-chlorophenyloamino)-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole in brain and plasma of animals: Application to a pharmacokinetic study

Raszewski G., Juszczak M., Lemieszek M. K., Matysiak J., Niewiadomy A., Rzeski W.

Acta Chromatographica

|

2014

|

Vol. 26, no. 2

255--266

EN

The development, optimization, and validation of a new high-performance liquid chromatography ultraviolet (HPLC-UV) method is presented for determining 2-(3-chlorophenyloamino)-5-(2,4-dihydroxy-phenyl)-1,3,4-thiadiazole (ClABT) in biological samples of rat plasma and brain tissue. ClABT was extracted directly from a plasma supernatant fraction following protein precipitation with acetonitrile and high speed centrifugation. Reverse phase HPLC separation was performed using an ODS-2 Hypersil column with the mobile phase consisting of 0.05 M triethylammonium phosphate buffer solution in acetonitrile and methanol (120:280:600, v/v/v), at room temperature, 1.2 mL min-1 flow rate, and UV-diode-array detection (DAD), at 335 nm. A linear response was obtained between 12.5 and 2000 ng mL-1 at analytically acceptable levels of precision (intra/inter-day) and accuracy. Mean recoveries ranged from 92.7% to 107.9%. It was concluded that the method was specific and precise and thus suitable for quantitative analysis in clinical pharmacokinetic studies of ClABT.

6

Using LC-MS/MS to study dauricine pharmacokinetics and determine its bioavailability following administration in different routes

Gao X., Jiang X., Wang L.

Acta Chromatographica

|

2013

|

Vol. 25, no. 2

241--256

EN

Dauricine has a variety of pharmacological properties including anti-inflammatory, anti-arrhythmic, and antihypertensive effects as well as reversing multidrug resistance (MDR) of cancer cells. While its therapeutic application is increasing, its bioavailability of different administration routes has not been studied. In the present study, we developed and validated a liquid chromatography/electrospray ionization mass spectrometry method (LC-MS/MS). Using this method, we quantified dauricine in rat plasma after administration via intravenous (i.v.) injection, per oral (p.o.), and intraperitoneal injection (i.p.). Our results indicated that this method detected plasma dauricine with a good linearity in the range of 1.95–1000.00 ng/mL (r = 0.9997). The extraction method showed an average intra- and inter-day recovery of 98.21–104.35% and 98.0–103.58%, respectively. Dauricine showed a fast absorption and widespread distribution after administration in all three tested routes. After intravenous administration (2.5, 5.0, 10.0 mg/kg), the pharmacokinetics of dauricine exhibited a first-order kinetics. In addition, dauricine showed a slow elimination with a long half-life (t1/2z) and double peaks phenomenon following p.o. and i.p. administration. Furthermore, using area under the plasma concentration-time curve (AUC), we calculated absolute bioavailability, which was over twofold higher when administered via i.p. than via p.o. administration. The newly obtained information from our study will provide important reference for dauricine dose and administration route in designing dauricine therapy for applicable diseases.